NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication
Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
